These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 28794905)

  • 1. Further Clinical Delineation of the MEF2C Haploinsufficiency Syndrome: Report on New Cases and Literature Review of Severe Neurodevelopmental Disorders Presenting with Seizures, Absent Speech, and Involuntary Movements.
    Vrečar I; Innes J; Jones EA; Kingston H; Reardon W; Kerr B; Clayton-Smith J; Douzgou S
    J Pediatr Genet; 2017 Sep; 6(3):129-141. PubMed ID: 28794905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MEF2C haploinsufficiency syndrome: Report of a new MEF2C mutation and review.
    Rocha H; Sampaio M; Rocha R; Fernandes S; Leão M
    Eur J Med Genet; 2016 Sep; 59(9):478-82. PubMed ID: 27255693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The MEF2C-Related and 5q14.3q15 Microdeletion Syndrome.
    Zweier M; Rauch A
    Mol Syndromol; 2012 Apr; 2(3-5):164-170. PubMed ID: 22670137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in MEF2C from the 5q14.3q15 microdeletion syndrome region are a frequent cause of severe mental retardation and diminish MECP2 and CDKL5 expression.
    Zweier M; Gregor A; Zweier C; Engels H; Sticht H; Wohlleber E; Bijlsma EK; Holder SE; Zenker M; Rossier E; Grasshoff U; Johnson DS; Robertson L; Firth HV; ; Ekici AB; Reis A; Rauch A
    Hum Mutat; 2010 Jun; 31(6):722-33. PubMed ID: 20513142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEF2C haploinsufficiency caused by either microdeletion of the 5q14.3 region or mutation is responsible for severe mental retardation with stereotypic movements, epilepsy and/or cerebral malformations.
    Le Meur N; Holder-Espinasse M; Jaillard S; Goldenberg A; Joriot S; Amati-Bonneau P; Guichet A; Barth M; Charollais A; Journel H; Auvin S; Boucher C; Kerckaert JP; David V; Manouvrier-Hanu S; Saugier-Veber P; Frébourg T; Dubourg C; Andrieux J; Bonneau D
    J Med Genet; 2010 Jan; 47(1):22-9. PubMed ID: 19592390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive investigation of the phenotype of MEF2C-related disorders in human patients: A systematic review.
    Cooley Coleman JA; Sarasua SM; Boccuto L; Moore HW; Skinner SA; DeLuca JM
    Am J Med Genet A; 2021 Dec; 185(12):3884-3894. PubMed ID: 34184825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MEF2C Haploinsufficiency features consistent hyperkinesis, variable epilepsy, and has a role in dorsal and ventral neuronal developmental pathways.
    Paciorkowski AR; Traylor RN; Rosenfeld JA; Hoover JM; Harris CJ; Winter S; Lacassie Y; Bialer M; Lamb AN; Schultz RA; Berry-Kravis E; Porter BE; Falk M; Venkat A; Vanzo RJ; Cohen JS; Fatemi A; Dobyns WB; Shaffer LG; Ballif BC; Marsh ED
    Neurogenetics; 2013 May; 14(2):99-111. PubMed ID: 23389741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microdeletion 5q14.3 and anomalies of brain development.
    Hotz A; Hellenbroich Y; Sperner J; Linder-Lucht M; Tacke U; Walter C; Caliebe A; Nagel I; Saunders DE; Wolff G; Martin P; Morris-Rosendahl DJ
    Am J Med Genet A; 2013 Sep; 161A(9):2124-33. PubMed ID: 23824879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ADGRV1 is implicated in myoclonic epilepsy.
    Myers KA; Nasioulas S; Boys A; McMahon JM; Slater H; Lockhart P; Sart DD; Scheffer IE
    Epilepsia; 2018 Feb; 59(2):381-388. PubMed ID: 29266188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroendocrine phenotypes in a boy with 5q14 deletion syndrome implicate the regulatory roles of myocyte-specific enhancer factor 2C in the postnatal hypothalamus.
    Sakai Y; Ohkubo K; Matsushita Y; Akamine S; Ishizaki Y; Torisu H; Ihara K; Sanefuji M; Kim MS; Lee KU; Shaw CA; Lim J; Nakabeppu Y; Hara T
    Eur J Med Genet; 2013 Sep; 56(9):475-83. PubMed ID: 23832106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electroclinical features of MEF2C haploinsufficiency-related epilepsy: A multicenter European study.
    Raviglione F; Douzgou S; Scala M; Mingarelli A; D'Arrigo S; Freri E; Darra F; Giglio S; Bonaglia MC; Pantaleoni C; Mastrangelo M; Epifanio R; Elia M; Saletti V; Morlino S; Vari MS; De Liso P; Pavaine J; Spaccini L; Cattaneo E; Gardella E; Møller RS; Marchese F; Colonna C; Gandioli C; Gobbi G; Ram D; Palumbo O; Carella M; Germano M; Tonduti D; De Angelis D; Caputo D; Bergonzini P; Novara F; Zuffardi O; Verrotti A; Orsini A; Bonuccelli A; De Muto MC; Trivisano M; Vigevano F; Granata T; Bernardina BD; Tranchina A; Striano P
    Seizure; 2021 May; 88():60-72. PubMed ID: 33831796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refining the phenotype associated with MEF2C haploinsufficiency.
    Novara F; Beri S; Giorda R; Ortibus E; Nageshappa S; Darra F; Dalla Bernardina B; Zuffardi O; Van Esch H
    Clin Genet; 2010 Nov; 78(5):471-7. PubMed ID: 20412115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotypes and Phenotypes of MEF2C Haploinsufficiency Syndrome: New Cases and Novel Point Mutations.
    Wan L; Liu X; Hu L; Chen H; Sun Y; Li Z; Wang Z; Lin Z; Zou L; Yang G
    Front Pediatr; 2021; 9():664449. PubMed ID: 34055696
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical findings from the landmark MEF2C-related disorders natural history study.
    Cooley Coleman JA; Sarasua SM; Moore HW; Boccuto L; Cowan CW; Skinner SA; DeLuca JM
    Mol Genet Genomic Med; 2022 Jun; 10(6):e1919. PubMed ID: 35416405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MEF2C deletions and mutations versus duplications: a clinical comparison.
    Novara F; Rizzo A; Bedini G; Girgenti V; Esposito S; Pantaleoni C; Ciccone R; Sciacca FL; Achille V; Della Mina E; Gana S; Zuffardi O; Estienne M
    Eur J Med Genet; 2013 May; 56(5):260-5. PubMed ID: 23402836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MEF2C-Related 5q14.3 Microdeletion Syndrome Detected by Array CGH: A Case Report.
    Shim JS; Min K; Lee SH; Park JE; Park SH; Kim M; Shim SH
    Ann Rehabil Med; 2015 Jun; 39(3):482-7. PubMed ID: 26161356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Refining the phenotype associated with MEF2C point mutations.
    Bienvenu T; Diebold B; Chelly J; Isidor B
    Neurogenetics; 2013 Feb; 14(1):71-5. PubMed ID: 23001426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microdeletions in 9q33.3-q34.11 in five patients with intellectual disability, microcephaly, and seizures of incomplete penetrance: is STXBP1 not the only causative gene?
    Ehret JK; Engels H; Cremer K; Becker J; Zimmermann JP; Wohlleber E; Grasshoff U; Rossier E; Bonin M; Mangold E; Bevot A; Schön S; Heilmann-Heimbach S; Dennert N; Mathieu-Dramard M; Lacaze E; Plessis G; de Broca A; Jedraszak G; Röthlisberger B; Miny P; Filges I; Dufke A; Andrieux J; Lee JA; Zink AM
    Mol Cytogenet; 2015; 8():72. PubMed ID: 26421060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5q14.3 Microdeletion Syndrome With Simultaneous Involvement of MEF2C and RASA1. Clinical Case and Review of the Literature.
    González Rodríguez J; de-la-Rosa Fernández E; Loizate Sarrionandia I; Benítez García E; Herrero Moyano M; Morales Moreno HJ; Suárez Hernández J
    Pediatr Dermatol; 2024 Sep; ():. PubMed ID: 39258307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5q14.3 neurocutaneous syndrome: a novel continguous gene syndrome caused by simultaneous deletion of RASA1 and MEF2C.
    Carr CW; Zimmerman HH; Martin CL; Vikkula M; Byrd AC; Abdul-Rahman OA
    Am J Med Genet A; 2011 Jul; 155A(7):1640-5. PubMed ID: 21626678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.